Evidence map›Paper›PMID 24065327›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014

Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid.

Taseera Kabanda, Mark J Siedner, Jeffrey D Klausner, Conrad Muzoora, David R Boulware

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01075152 (Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis), which is not on this map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01075152 phase4completednot on this map

Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis

TypeinterventionalSponsorUniversity of MinnesotaRan2010 to 2013Enrolled177ConditionsCryptococcal Meningitis, HIV Infections, AIDSArmsefavirenz, nucleoside
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Cryptococcal antigen cross-reactivity is associated with fatal trichosporonosis in patients with hematologic diseases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Recurrence of Symptoms Following Cryptococcal Meningitis: Characterizing a Diagnostic Conundrum With Multiple Etiologies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  20. Cryptococcus neoformans, a global threat to human health.Infectious diseases of poverty · 2023
    Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Taseera KabandaDepartment of Medicine, Faculty of Medicine, Mbarara University of Science and Technology, Uganda.
Mark J Siedner
Jeffrey D Klausner
Conrad Muzoora
David R Boulware
Mbarara University of Science and Technology · UGMassachusetts General Hospital · USUniversity of California, Los Angeles · USUniversity of Minnesota · US

Funding

PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Trial for the Optimal Timing of HIV Therapy after Cryptococcal MeningitisU01AI089244 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2010 to 2014
$7.6M
Behavioral Aspects of Low-cost Medical Devices to Improve HIV CareK23MH099916 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI SIEDNER, MARK J · 2013 to 2017
$917k
Immune Reconstitution Syndrome in HIV infected Persons in Resource-Limited AreasK23AI073192 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2009 to 2012
$530k
Medical Research CouncilNIAID NIH HHS K23 AI073192NIAID NIH HHS K23AI073192NIAID NIH HHS T32 AI007433NIAID NIH HHS T32AI007433NIAID NIH HHS U01 AI089244NIAID NIH HHS U01AI089244NIMH NIH HHS K23 MH099916PHS HHS K23099916
6 · The paper itself

Abstract

The cryptococcal antigen (CRAG) lateral flow assay (LFA) had 100% sensitivity and specificity on cerebrospinal fluid samples. Pretreatment LFA titers correlated with quantitative cultures (R(2) = 0.7) and predicted 2- and 10-week mortality. The CRAG LFA is an accurate diagnostic assay for CSF and should be considered for point-of-care diagnosis of cryptococcal meningitis.

Indexed as

Point-of-Care SystemsCerebrospinal FluidChromatography, AffinityCohort StudiesCryptococcusHumansMeningitis, CryptococcalSensitivity and Specificitycryptococcal meningitisdiagnosisHIVpoint-of-caresub-Saharan Africa

Identifiers

PMID24065327
PMCPMC3864499
OpenAlexW2100651734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.